Biomarin

BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
Endpoints
Biomarin
FDA
pegvaliase
PDUFA
Flag link:
Biomarin announces new investments in Ireland
Biomarin announces new investments in Ireland
GoInPharma
Biomarin
Ireland
Flag link:
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Flag link:
BioMarin, Spark, raising the stakes for hemophilia
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
Flag link:
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
CNBC
Biomarin
Brineura
drug pricing
Batten disease
Flag link:
4 Drug Stocks With Big News Coming in April
4 Drug Stocks With Big News Coming in April
Motley Fool
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
Flag link:
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Biomarin
earnings
Vimizim
Kuvan
Naglazyme
Flag link:
BioMarin sues to stop generic version of its $90K-a-year drug
BioMarin sues to stop generic version of its $90K-a-year drug
Bizjournals.com
Biomarin
generics
Kuvan
Dr Reddy's
Flag link:
Biotech Investing: 3 Bold Predictions for 2017
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
biotech
Incyte
Biogen
Biomarin
Gilead Sciences
Illumina
Flag link:
7 of the Most Shocking Biotech Pipeline Blowups of 2016
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
Flag link:
BioMarin’s Disappointing 3Q16 Earnings
BioMarin’s Disappointing 3Q16 Earnings
Market Realist
Biomarin
earnings
Flag link:
Sarepta Therapeutics' Greatest Threat: Anthem?
Sarepta Therapeutics' Greatest Threat: Anthem?
Motley Fool
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 5
Biomarin
Anthem
Flag link:
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
FDA’s controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin
Endpoints
FDA
eteplirsen
Duchenne Muscular Dystrophy
Biomarin
Sarepta Therapeutics
Flag link:
3 Biotechs Most Likely to Be Acquired
3 Biotechs Most Likely to Be Acquired
Motley Fool
biotech
M&A
Incyte
Biomarin
Biogen
Flag link:
After Sarepta win, BioMarin appeals DMD patent ruling
After Sarepta win, BioMarin appeals DMD patent ruling
BioPharma Dive
Sarepta Therapeutics
Biomarin
patents
Duchenne Muscular Dystrophy
eteplirsen
Kyndrisa
Flag link:
BioMarin hits snag with latest rare disease drug
BioMarin hits snag with latest rare disease drug
BioPharma Dive
Biomarin
Brineura
FDA
CLN2 disease
Flag link:
3 Biotech Stocks Could Be the Next Big Takeover Targets
3 Biotech Stocks Could Be the Next Big Takeover Targets
24/7 Wall St
biotech
M&A
Biomarin
Incyte
Tesaro
Flag link:
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss
Barron's
biotech
M&A
Gilead Sciences
Sanofi
Medivation
Incyte
Biomarin
Tesaro
Seattle Genetics
Flag link:
Sarepta: The Competition Is At The Gate
Sarepta: The Competition Is At The Gate
Seeking Alpha
Sarepta Therapeutics
eteplirsen
Biomarin
Summit Therapeutics
PTC Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Why BioMarin's Shares Tumbled 11% in June
Why BioMarin's Shares Tumbled 11% in June
Motley Fool
Biomarin
M&A
Duchenne Muscular Dystrophy
Sanofi
drisapersen
Kyndrisa
Flag link: